Advice

following an abbreviated submission:

vigabatrin (Kigabeq®) is accepted for restricted use within NHSScotland.

Indication under review: In infants and children from 1 month to less than 7 years of age for:

  • treatment in monotherapy of infantile spasms (West's syndrome)

  • treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.

SMC restriction: patients in whom other formulations of vigabatrin are not suitable.

Vigabatrin 500mg soluble tablets are considered bioequivalent to vigabatrin 500mg granules for oral solution. Vigabatrin soluble tablets are more expensive than vigabatrin granules for oral solution. Overall net budget impact is likely to be small.

Download detailed advice721KB (PDF)

Download

Medicine details

Medicine name:
vigabatrin (Kigabeq)
SMC ID:
SMC2352
Indication:

in infants and children from 1 month to less than 7 years of age for:

• treatment in monotherapy of infantile spasms (West's syndrome).

• treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.

Pharmaceutical company
Veriton Pharma
BNF chapter
Central nervous system
Submission type
Abbreviated
Status
Restricted
Date advice published
07 June 2021